UNIVERSITY OF PRETORIA Patent applications |
Patent application number | Title | Published |
20150176006 | NUCLEIC ACIDS FOR DOWN-REGULATION OF GENE EXPRESSION - Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided. | 06-25-2015 |
20150174059 | ORAL CARE - Various disclosed embodiments relate to oral care are presented. In particular, one embodiments includes to an oral care composition for inhibiting the growth of potentially pathogenic oral microorganisms, said composition comprising an extract of | 06-25-2015 |
20150118337 | EXTRACT OF GREYIA RADLKOFERI AND USE THEREOF - This invention relates to the isolation, and use of a plant extract in the treatment of skin hyper-pigmentation. More particularly, this invention relates to the isolation of a tyrosinase inhibitor in an extract of plant material from the | 04-30-2015 |
20150111219 | LIPOSOMAL COMPOSITION COMPRISING A STEROL-MODIFIED LIPID AND A PURIFIED MYCOBACTERIAL LIPID CELL WALL COMPONENT AND ITS USE IN THE DIAGNOSIS OF TUBERCULOSIS - A liposomal composition comprising a sterol-modified lipid and a purified mycobacterial lipid cell wall component or analog or derivative thereof is described. The composition is useful as a lipid antigen-presenting vehicle for the detection of lipid antigen specific biomarker antibodies in antibody containing biological samples in the diagnosis of active tuberculosis. The purified lipid cell wall component is typically a purified mycolic acid or a mixture of mycolic acids from a | 04-23-2015 |
20140120133 | Vaccine Against African Horse Sickness Virus - The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions. | 05-01-2014 |
20140008205 | FLUIDISED BED PYROLYSIS APPARATUS AND METHOD - A carbonaceous feed pyrolysis apparatus is provided including two or more hot particle fluidised beds, and one or more positive displacement apparatus for the transfer of hot particles between two or more of the beds, wherein one or more of the fluidised beds contains a combustion zone. A bio-oil production process is also provided, including pyrolysis of a carbonaceous bio-mass using two or more fluidized beds, including a first combustion zone carried out in one or more combustion fluidized beds in which a particulate material is fluidized and heated, and a second pyrolysis zone carried out in one or more pyrolysis fluidized beds in which the hot particles heated in the combustion zone are used for pyrolysis of the bio-mass. | 01-09-2014 |
20130150461 | PROCESS FOR PRODUCING PROTEIN MICROPARTICLES - The present invention relates to a process for producing protein microparticles in dilute organic acid solutions and in the absence of an alcohol such as ethanol. The microparticles are formed by dissolving a cereal prolamin protein in a concentrated organic acid solution with agitation and then diluting the solution with an aqueous solution. Protein microparticles having vacuoles are thus formed. The protein microparticles may be used to form powders, films, coatings, matrices, scaffolds and the like. Complete films can be formed from the protein microparticles of the invention. | 06-13-2013 |
20130137598 | METHOD OF DETECTING SURROGATE MARKERS IN A SERUM SAMPLE - The invention provides a method of detecting surrogate markers for active tuberculosis in a serum sample. The surrogate markers are selected from serum mycolic acid antigen, serum anti-mycolic acid antibodies or both. The method includes the steps of combining the serum sample with a labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acids to produce a combined serum sample, the antibody or fragment thereof not substantially cross-reacting with cholesterol and the label being selected so that binding of the labelled antibody to immobilized mycolic acid antigen of mycobacterial origin produces a detectable signal and combining a blank sample with the labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acid to produce a combined blank sample. The method includes exposing both samples to immobilised mycolic acid antigen of mycobacterial origin or a synthetic analogue or analogues thereof so that the labelled immunoglobulin antibodies or fragments thereof in each sample bind to the immobilised antigen to produce detectable signals. If the surrogate markers are present, the signal produced by the blank sample will be stronger than that produced by the serum sample because of inhibition of binding of the labelled antibody in the serum sample arising from prior binding of the labelled antibody with the mycolic acid antigen in the serum sample or by competitive binding of serum anti-mycolic acid antibodies in the serum sample to the immobilised mycolic acid antigen or both. | 05-30-2013 |
20130022972 | OLIGONUCLEOTIDES AND METHODS FOR DETECTING LAVENDER FOAL SYNDROME - A method for detecting a genetic polymorphism associated with Lavender Foal Syndrome or a predisposition thereto in a subject, the method including screening a genomic material sample from the subject for the presence of at least one polymorphism in a MYO5A gene. | 01-24-2013 |
20120128779 | PROCESS FOR PRODUCING PROTEIN MICROPARTICLES - The present invention relates to a process for producing protein microparticles in dilute organic acid solutions and in the absence of an alcohol such as ethanol. The microparticles are formed by dissolving a cereal prolamin protein in a concentrated organic acid solution with agitation and then diluting the solution with an aqueous solution. Protein microparticles having vacuoles are thus formed. The protein microparticles may be used to form powders, films, coatings, matrices, scaffolds and the like. Complete films can be formed from the protein microparticles of the invention. | 05-24-2012 |
20110251289 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER - The invention provides a method of preparing the stereoisomers of 1,11-diamino-6-aza-undecane-2,4,8,10-tetraol. | 10-13-2011 |